MEK inhibitors, such as trametinib and selumetinib, have shown limited efficacy as monotherapies, but their combinations with other targeted therapies, including BRAF inhibitors (e.g., dabrafenib), have demonstrated improved outcomes in BRAF V600E-mutant NSCLC. This evidence concerns the gene BRAF and non-small cell lung carcinoma.